Biogen Idec CEO James Mullen: An Interview With “The Pink Sheet” DAILY
This article was originally published in The Pink Sheet Daily
Company is “open for business” on deals, Mullen says during break at Massachusetts Biotechnology Council investor conference.
You may also be interested in...
Alnylam’s RNAi technology will be directed at progressive multifocal leukoencephalopathy, the brain disease associated with Biogen’s MS therapy Tysabri.
Acquisition follows the release of positive Phase II study results of BG-12 in relapsing-remitting MS.
The company expects the bulk of expenditures from a $200 mil. business development plan will go toward up-front milestones and new clinical costs for in-licensed drugs.